Non-Hodgkin Lymphoma - Pipeline Review, H1 2016

Description: Non-Hodgkin Lymphoma - Pipeline Review, H1 2016

Summary


The report provides comprehensive information on the therapeutics under development for Non-Hodgkin Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non-Hodgkin Lymphoma and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma
- The report reviews pipeline therapeutics for Non-Hodgkin Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Non-Hodgkin Lymphoma therapeutics and enlists all their major and minor projects
- The report assesses Non-Hodgkin Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Non-Hodgkin Lymphoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Non-Hodgkin Lymphoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

Introduction

Non-Hodgkin Lymphoma Overview

Therapeutics Development

Non-Hodgkin Lymphoma - Therapeutics under Development by Companies

Non-Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes

Non-Hodgkin Lymphoma - Pipeline Products Glance

Non-Hodgkin Lymphoma - Products under Development by Companies

Non-Hodgkin Lymphoma - Products under Investigation by Universities/Institutes

Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development

Non-Hodgkin Lymphoma - Therapeutics Assessment

Drug Profiles

Non-Hodgkin Lymphoma - Recent Pipeline Updates

Non-Hodgkin Lymphoma - Dormant Projects

Non-Hodgkin Lymphoma - Discontinued Products

Non-Hodgkin Lymphoma - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Non-Hodgkin Lymphoma, H1 2016

Number of Products under Development for Non-Hodgkin Lymphoma - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Development by Companies, H1 2016 (Contd..3)

Number of Products under Development by Companies, H1 2016 (Contd..4)

Number of Products under Development by Companies, H1 2016 (Contd..5)

Number of Products under Development by Companies, H1 2016 (Contd..6)

Number of Products under Development by Companies, H1 2016 (Contd..7)

Number of Products under Development by Companies, H1 2016 (Contd..8)
Number of Products under Development by Companies, H1 2016 (Contd..9)
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Comparative Analysis by Unknown Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016 (Contd..1)
Products under Development by Companies, H1 2016 (Contd..2)
Products under Development by Companies, H1 2016 (Contd..3)
Products under Development by Companies, H1 2016 (Contd..4)
Products under Development by Companies, H1 2016 (Contd..5)
Products under Development by Companies, H1 2016 (Contd..6)
Products under Development by Companies, H1 2016 (Contd..7)
Products under Development by Companies, H1 2016 (Contd..8)
Products under Development by Companies, H1 2016 (Contd..9)
Products under Development by Companies, H1 2016 (Contd..10)
Products under Development by Companies, H1 2016 (Contd..11)
Products under Development by Companies, H1 2016 (Contd..12)
Products under Development by Companies, H1 2016 (Contd..13)
Products under Development by Companies, H1 2016 (Contd..14)
Products under Development by Companies, H1 2016 (Contd..15)
Products under Development by Companies, H1 2016 (Contd..16)
Products under Development by Companies, H1 2016 (Contd..17)
Products under Investigation by Universities/Institutes, H1 2016
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
Non-Hodgkin Lymphoma - Pipeline by 4SC AG, H1 2016
Non-Hodgkin Lymphoma - Pipeline by AB Science SA, H1 2016
Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Actelion Ltd, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by ADC Therapeutics Sarl, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Affimed GmbH, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Allinky Biopharma, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Altor BioScience Corporation, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Amgen Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Angimmune LLC, H1 2016
Non-Hodgkin Lymphoma - Pipeline by arGEN-X BV, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Ariad Pharmaceuticals, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Arno Therapeutics, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by AstraZeneca Plc, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Atara Biotherapeutics, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Bayer AG, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by BioAtla, LLC, H1 2016
Non-Hodgkin Lymphoma - Pipeline by BioInvent International AB, H1 2016
Non-Hodgkin Lymphoma - Pipeline by BioLineRx, Ltd., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Bionovis SA, H1 2016
Non-Hodgkin Lymphoma - Pipeline by BioSight Ltd., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Boston Biomedical, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Calithera Biosciences, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Celgene Corporation, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Cell Medica Limited, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Celldex Therapeutics, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by CellInvest S.A., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Celltrion, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Celon Pharma Sp. z o.o., H1 2016
Non-Hodgkin Lymphoma - Pipeline by CerRx, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Chipscreen Biosciences Ltd, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Clonz Biotech Private Limited, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Coherus BioSciences, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Dicerna Pharmaceuticals, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Eisai Co., Ltd., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Eli Lilly and Company, H1 2016
Non-Hodgkin Lymphoma - Pipeline by EpiZyme, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Formula Pharmaceuticals, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Galderma S.A., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Gamida Cell Ltd., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Genosco, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Genzyme Corporation, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Grupo Ferrer Internacional, S.A., H1 2016
Non-Hodgkin Lymphoma - Pipeline by iDD biotech SAS, H1 2016
Non-Hodgkin Lymphoma - Pipeline by IGF Oncology, LLC., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Immune Design Corp., H1 2016
Non-Hodgkin Lymphoma - Pipeline by ImmunoGen, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Immunomedics, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Incyte Corporation, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Innate Pharma S.A., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Innoven Biologics, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Johnson & Johnson, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Juno Therapeutics Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Kainos Medicine, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Komipharm International Co., Ltd., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016
Non-Hodgkin Lymphoma - Pipeline by MedImmune, LLC, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Merck KGaA, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by miRagen Therapeutics, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Mirna Therapeutics, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by MorphoSys AG, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Mundipharma International Ltd, H1 2016
Non-Hodgkin Lymphoma - Pipeline by NantKwest, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Neumedicines Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Nordic Nanovector ASA, H1 2016
Non-Hodgkin Lymphoma - Pipeline by NovaLead Pharma Pvt. Ltd., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Novartis AG, H1 2016
Non-Hodgkin Lymphoma - Pipeline by OncoSec Medical Incorporated, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Onxeo SA, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Oxford BioTherapeutics Ltd, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Panacea Biotec Limited, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Pfizer Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Pharma Mar, S.A., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Polyphor Ltd., H1 2016
Non-Hodgkin Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Rhizen Pharmaceuticals S.A., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Richter Gedeon Nyrt., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Sanofi, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Sareum Holdings Plc, H1 2016
Non-Hodgkin Lymphoma - Pipeline by SciTech Development, LLC, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Shanghai Pharmaceutical Co., Ltd., H1 2016
Non-Hodgkin Lymphoma - Pipeline by SialoTec GmbH, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Sigma-Tau S.p.A., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Solasia Pharma K.K., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Soligenix, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Sorrento Therapeutics, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Stemline Therapeutics, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Supratek Pharma Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Taiwan Liposome Company, Ltd., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Targazyme, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by TetraLogic Pharmaceuticals, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016
Non-Hodgkin Lymphoma - Pipeline by TG Therapeutics, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Theravectys SA, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Transgene Biotek Limited, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Trillium Therapeutics Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Unum Therapeutics, Inc., H1 2016
Non-Hodgkin Lymphoma - Pipeline by Xenetic Biosciences (UK) Limited, H1 2016
Non-Hodgkin Lymphoma - Pipeline by Zymeworks Inc., H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Non-Hodgkin Lymphoma Therapeutics - Recent Pipeline Updates, H1 2016
Non-Hodgkin Lymphoma - Dormant Projects, H1 2016
Non-Hodgkin Lymphoma - Dormant Projects (Contd..1), H1 2016
Non-Hodgkin Lymphoma - Dormant Projects (Contd..2), H1 2016
Non-Hodgkin Lymphoma - Dormant Projects (Contd..3), H1 2016
Non-Hodgkin Lymphoma - Dormant Projects (Contd..4), H1 2016
Non-Hodgkin Lymphoma - Dormant Projects (Contd..5), H1 2016
Non-Hodgkin Lymphoma - Dormant Projects (Contd..6), H1 2016
Non-Hodgkin Lymphoma - Dormant Projects (Contd..7), H1 2016
Non-Hodgkin Lymphoma - Dormant Projects (Contd..8), H1 2016
Non-Hodgkin Lymphoma - Dormant Projects (Contd..9), H1 2016
Non-Hodgkin Lymphoma - Dormant Projects (Contd..10), H1 2016
Non-Hodgkin Lymphoma - Dormant Projects (Contd..11), H1 2016
Non-Hodgkin Lymphoma - Dormant Projects (Contd..12), H1 2016
Non-Hodgkin Lymphoma - Dormant Projects (Contd..13), H1 2016
Non-Hodgkin Lymphoma - Dormant Projects (Contd..14), H1 2016
Non-Hodgkin Lymphoma - Dormant Projects (Contd..15), H1 2016
Non-Hodgkin Lymphoma - Dormant Projects (Contd..16), H1 2016
Non-Hodgkin Lymphoma - Discontinued Products, H1 2016
Non-Hodgkin Lymphoma - Discontinued Products (Contd..1), H1 2016
Non-Hodgkin Lymphoma - Discontinued Products (Contd..2), H1 2016
Non-Hodgkin Lymphoma - Discontinued Products (Contd..3), H1 2016
Non-Hodgkin Lymphoma - Discontinued Products (Contd..4), H1 2016
List of Figures
Number of Products under Development for Non-Hodgkin Lymphoma, H1 2016
Number of Products under Development for Non-Hodgkin Lymphoma - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Top 10 Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Top 10 Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Top 10 Molecule Types, H1 2016
Number of Products by Stage and Top 10 Molecule Types, H1 2016

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3766812/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Non-Hodgkin Lymphoma - Pipeline Review, H1 2016
Web Address: http://www.researchandmarkets.com/reports/3766812/
Office Code: SCPLJFQT

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Single User:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Site License:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
<td>USD 6000</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
</tr>
<tr>
<td>Email Address:</td>
<td>*</td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:
Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World